And then, 10 months after going public, the company secured approval for that NMOSD drug, now known as Uplizna. The 2-1 split was announced on Friday, June 26th 2015. Fundamental company data provided by Zacks Investment Research. In a Monday statement, Horizon CEO Tim Walbert said his company plans on maximizing "the full potential of Viela’s pipeline, including the pursuit of additional future indications.". View which stocks are hot on social media with MarketBeat's trending stocks report. Gene therapy developers will need to address a series of setbacks that have shaded optimism in the sector's fast growth. 8) Limited, Zeneca Epsilon – Produtos Farmacêuticos Lda, Zeneca Finance (Netherlands) Company, Zeneca Holdings Inc., Zeneca Ilac Sanayi Ve Ticaret Anonim Sirketi, Zeneca Inc., Zeneca Wilmington Inc., and Zenecapharma Produtos Farmaceuticos . Learn more. 13 equities research analysts have issued 12 month price targets for AstraZeneca's shares. Please log in to your account or sign up in order to add this asset to your watchlist. Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 71.54% next year. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. It went public in 2019 at $19 per share, won its first drug approval in 2020, and is now set up to be acquired in 2021. Get daily stock ideas top-performing Wall Street analysts. The ex-dividend date is Thursday, February 25th. Eurofins Viracor BioPharma Launches PanCancerIQ Comprehensive Genomic Profiling Service to A... TABMELT® Granted Patent Rights in Russia, Expanding Vivera Global Licensing, The U.S. Is Sitting on Tens of Millions of Vaccine Doses the World Needs, After US approval Aveo faces a monumental task, Reining in drug patents isn't a silver bullet against high drug prices. Price to Earnings Ratio vs. the Market. The P/E ratio of Alexion Pharmaceuticals is 35.39, which means that it is trading at a more expensive … AstraZeneca has a PEG Ratio of 1.18. AZN AstraZeneca $48.67 / -1.14 (-2.29%) 03/03/21 U.S. District Court rules in AstraZeneca's favor in Symbicort patent litigation 03/02/21 AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX How Rocket Pharma quietly became one of gene therapy's high flyers, Detailed Lilly data give mixed picture of Alzheimer's drug's benefit, Acadia shares plunge after unexpected FDA feedback, FDA sets meeting to review 6 speedy cancer drug approvals as evaluation widens, How to Accelerate Time to Market by Optimizing Manufacturing, Enhancing Time to Market Without Compromising Efficacy, Inside the rapidly changing world of gene therapy. AstraZeneca has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. View AstraZeneca's Short Interest. The following companies are subsidiares of AstraZeneca: AAPM Sar, AZ Reinsurance Limited, AZ-Mont Insurance Company, AZENCO2 Limited, AZENCO4 Limited, Acerta Pharma B.V., Acerta Pharma LLC, AcertaPharma, Aktiebolaget Hassle, Alexion Pharmaceuticals, Almirall, AlphaCore Pharma, Amylin Ohio LLC, Amylin Pharmaceuticals LLC, Archigen Biotech Limited, Ardea Biosciences, Ardea Biosciences Limited, Arrow Therapeutics, Arrow Therapeutics Limited, Aspire Therapeutics B.V., Astra Alpha Produtos Farmaceuticos Lda, Astra Export & Trading Aktiebolag, Astra Lakemedel Aktiebolag, Astra Pharmaceuticals Limited, Astra Tech International Aktiebolag, AstraPharm, AstraZeneca (Israel) Ltd, AstraZeneca (Thailand) Limited, AstraZeneca (Wuxi) Trading Co. Ltd, AstraZeneca A/S, AstraZeneca AB, AstraZeneca AG, AstraZeneca AS, AstraZeneca Asia-Pacific Business Services Sdn Bhd, AstraZeneca B.V., AstraZeneca BioVentureHub AB, AstraZeneca Biotech AB, AstraZeneca Bulgaria EOOD, AstraZeneca CAMCAR Costa Rica S.A., AstraZeneca CAMCAR S.A., AstraZeneca Canada Inc., AstraZeneca China UK Limited, AstraZeneca Collaboration Ventures LLC, AstraZeneca Colombia S.A.S., AstraZeneca Continent B.V., AstraZeneca Czech Republic s.r.o., AstraZeneca Death In Service, AstraZeneca Dunkerque Production SCS, AstraZeneca Eesti OÜ, AstraZeneca Egypt for Pharmaceutical Industries JSC, AstraZeneca Egypt for Trading LLC, AstraZeneca Employee Share Trust Limited, AstraZeneca FZ-LLC, AstraZeneca Farmaceutica Chile Limitada, AstraZeneca Farmaceutica Holding Spain S.A., AstraZeneca Farmaceutica Spain S.A., AstraZeneca Finance Limited, AstraZeneca Finance S.A.S., AstraZeneca Gamma B.V., AstraZeneca GmbH, AstraZeneca Health Care Division S.A. de C.V., AstraZeneca Holding Aktiebolag, AstraZeneca Holding France S.A.S., AstraZeneca Holding GmbH, AstraZeneca Holdings B.V., AstraZeneca Holdings Pty Limited, AstraZeneca Hong Kong Limited, AstraZeneca Ilac Sanayi ve Ticaret Limited Sirketi, AstraZeneca India Private Limited, AstraZeneca Industries LLC, AstraZeneca Intermediate Holdings Limited, AstraZeneca International Holdings Aktiebolag, AstraZeneca Investment (China) Co. Ltd, AstraZeneca Investments Limited, AstraZeneca Japan Limited, AstraZeneca Jota B.V., AstraZeneca K.K., AstraZeneca Kft, AstraZeneca Korea Co. Ltd, AstraZeneca Latvija SIA, AstraZeneca Lietuva UAB, AstraZeneca Limited, AstraZeneca Luxembourg S.A., AstraZeneca Maroc SARLAU, AstraZeneca Nigeria Limited, AstraZeneca Nominees Limited, AstraZeneca Nordic AB, AstraZeneca OY., AstraZeneca PTY Limited, AstraZeneca Pars Company, AstraZeneca Peru S.A., AstraZeneca Pharma India Limited, AstraZeneca Pharma Poland Sp.z.o.o., AstraZeneca Pharma S.R.L., AstraZeneca Pharmaceutical (China) Co. Ltd, AstraZeneca Pharmaceuticals (Ireland) Designated Activity Company, AstraZeneca Pharmaceuticals (Phils.) Pre-Market earnings guidance on Thursday, February, 11th. MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Wall Street analysts have given AstraZeneca a "Buy" rating, but there may be better short-term opportunities in the market. The free newsletter covering the top industry headlines, By signing up to receive our newsletter, you agree to our, Press release from EUROFINS VIRACOR BIOPHARMA SERVICES, Press release from Vivera Pharmaceuticals, Central Europe Summer Time (UTC +2) • Online, • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. AstraZeneca had a net margin of 9.65% and a trailing twelve-month return on equity of 37.23%. It’s catching on… again. ", Follow AstraZeneca will. AstraZeneca declared a semi-annual dividend on Friday, February 12th. See more. This puts Pascal Soriot in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA … Nov 20, 2020 Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time. The newly created shares were distributed to shareholders after the market closes on Friday, July 24th 2015. Here's what we may learn. View our earnings forecast for AstraZeneca. Learn about financial terms, types of investments, trading strategies and more. View AstraZeneca's dividend history. Twitter, Follow 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 The dividend payout ratio of AstraZeneca is 106.29%. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. AZN stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Dodge & Cox, Morgan Stanley, Primecap Management Co. CA, Stifel Financial Corp, Nuveen Asset Management LLC, and Lord Abbett & CO. LLC. Entrench definition is - to place within or surround with a trench especially for defense. Saama Teams with Oracle to Offer Life Sciences Industry AI-Enabled Applications to Accelera... Cryoport Appoints Mind+Matter As Part Of A Global Brand Development Tender, UBC Announces Initiative To Accelerate COVID-19 Vaccine Real-World Evidence, Taking a page from Celgene, Takeda builds and buys a cancer biotech, Biotech's deal refusals led to pricey buyout by Merck, Amgen, with rare buyout, pays $1.9B for cancer biotech Five Prime, Doudna-founded biotech Caribou raises fresh funds to fuel gene editing pipeline, Takeda takes full control of drug for rare epilepsies. These assets will further our product availability and service capabilities to the fire protection industry in the western United States. Once completed, the deal would hand Horizon three clinical-stage drugs targeting inflammatory and autoimmune diseases. Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. How to use entrench in a sentence. AstraZeneca does not have a long track record of dividend growth. The British drugmaker established Viela in February 2018. The company reported $0.54 EPS for the quarter, missing analysts' consensus estimates of $0.68 by $0.14. Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more. Based on an average trading volume of 11,210,000 shares, the short-interest ratio is presently 5.9 days. Earnings for Alexion Pharmaceuticals are expected to grow by 5.30% in the coming year, from $11.14 to $11.73 per share. “Made in the UK”. For example, the drug is late-stage testing for myasthenia gravis, a rare neuromuscular disorder that has been at the center of other recent biotech acquisitions. Export data to Excel for your own analysis. Learn more. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. He noted, too, that while his team has been cautious about the sales opportunity for Uplizna in the NMOSD drug market, it generally holds a "favorable view" on Viela's emerging pipeline, "which seems to be the key driver of the acquisition. Compare Top Brokerages Here. On average, they expect AstraZeneca's share price to reach $89.50 in the next year. AstraZeneca is headquartered at 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Researchers are also looking at other applications of Uplizna. on This indicates that AstraZeneca will be able to sustain or increase its dividend. View all of AZN's competitors. As of January 29th, there was short interest totaling 65,920,000 shares, an increase of 32.0% from the January 14th total of 49,930,000 shares. View insider buying and selling activity for AstraZeneca or or view top insider-buying stocks. This suggests a possible upside of 84.8% from the stock's current price. AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. New Delhi, Feb 19 (PTI) Property and home loan brokerage firm Square Yards on Friday said it has acquired PropsAMC, a data intelligence, asset management and real estate services firm. AstraZeneca has a market capitalization of $127.08 billion and generates $24.38 billion in revenue each year. Among those molecules was a potential treatment for NMOSD, a rare condition that causes loss of vision and mobility problems, and affects an estimated 10,000 people in the U.S. About a year and a half after forming, Viela raised around $150 million through an initial public offering. But, as recent setbacks have shown, reserachers and drugmakers still face major challenges. Paroxysmal definition, sudden and uncontrolled: In 2 years of continuous observations, volcanic activity included minor explosions, persistent degassing, paroxysmal eruptions, and lava flows.This region of the world is going through paroxysmal changes, and ongoing humanitarian aid is a critical need. AstraZeneca saw a increase in short interest in the month of January. Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche (RHHBY), Abbott Laboratories (ABT), Eli Lilly and (LLY), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Merck & Co., Inc. (MRK), Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), Sanofi (SNY), CSL (CSLLY), GlaxoSmithKline (GSK), Zoetis (ZTS) and Bayer Aktiengesellschaft (BAYRY). MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. AstraZeneca is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021. Get short term trading ideas from the MarketBeat Idea Engine. ), AstraZeneca has received 8 “underperform” votes. One of them, VIB7734, inhibits an immune system-regulating protein called ILT7, and is being evaluated as a possible treatment for different kinds of lupus as well as acute lung injury related to COVID-19. Biological E acquires Akorn India; COVID-19 exposes India’s underinvestment in healthcare; Centre will achieve goal of TB-Free India by 2025, says Harsh Vardhan; Infectious COVID-19 mutation may be a good thing, says disease expert; Delhi to make oximeters available in 30,000 villages to help in … AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). All rights reserved. (Add your “underperform” vote.). AstraZeneca has received a consensus rating of Buy. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. Nov 10, 2020 The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. Only 15.57% of the stock of AstraZeneca is held by institutions. View analysts' price targets for AstraZeneca or view top-rated stocks among Wall Street analysts. Ben Fidler You may vote once every thirty days. Sentynl acquires CUTX-101, Copper Histidinate, for $20 million in upfront and regulatory milestone payments through NDA approval, as well as potential sales milestones plus royalties AstraZeneca Plc, one of the drugmakers on the front lines of COVID-19 vaccine efforts, said earnings growth will accelerate this year as its turnaround efforts pay off. Payout ratios above 75% are not desirable because they may not be sustainable. (Add your “outperform” vote. 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. AstraZeneca has received 9 “outperform” votes. Payout ratios above 75% are not desirable because they may not be sustainable. Though Horizon has been quieter on the M&A front lately, the company's bid for Viela represents its largest purchase to date. View AstraZeneca's dividend history. Earnings for AstraZeneca are expected to grow by 30.00% in the coming year, from $2.00 to $2.60 per share. Vice-Pres of Operations & Information Technology, Exec. View insider buying and selling activity for AstraZeneca or view top insider-selling stocks. AstraZeneca to Acquire Alexion, Accelerating the Company's Strategic and Financial Development. Horizon will pay $53 per share for Viela, which in June won U.S. approval for Uplizna, a treatment for the rare autoimmune disease neuromyelitis optica spectrum disorder, or NMOSD. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. AstraZeneca has a portfolio of products for major diseases including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation areas.. Jacob Bell Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Profit excluding some items will be US$4.75 a share to US$5 a share, the drugmaker said in a statement Thursday. AstraZeneca employs 76,100 workers across the globe. Find 42 ways to say semblance, along with antonyms, related words, and example sentences at Thesaurus.com, the world's most trusted free thesaurus. View AstraZeneca's earnings history. AZN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Voloridge Investment Management LLC, Price T Rowe Associates Inc. MD, Avidity Partners Management LP, First Trust Advisors LP, PFM Health Sciences LP, Clark Capital Management Group Inc., and KAMES CAPITAL plc. One share of AZN stock can currently be purchased for approximately $48.42. This is a positive change from AstraZeneca's previous semi-annual dividend of $0.45. Dive Brief: Horizon Therapeutics has agreed to acquire Viela Bio, a spinout of AstraZeneca, in a deal that values the Maryland-based biotech at roughly $3 billion. In the past three months, AstraZeneca insiders have not sold or bought any company stock. The official website for AstraZeneca is www.astrazeneca.com. Vice-Pres of BioPharmaceuticals R&D, Exec. AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company provided earnings per share guidance of 4.75-5.00 for the period, compared to the Thomson Reuters consensus estimate of $2.95. View which stocks have been most impacted by COVID-19. Pascal Soriot has an approval rating of 98% among AstraZeneca's employees. The company can be reached via phone at 44 20 3749 5000 or via email at [email protected]. Jun 27 – Jul 1, 2021, an unusually large amount of initial funding. View analyst ratings for AstraZeneca or view top-rated stocks. Derek Archila, an analyst at Stifel, wrote in a note that his team does not expect another bidder to challenge Horizon's offer. AstraZeneca updated its FY 2021 Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. H3R Clean Agents has built a reputation for their knowledge and top-quality products and services and will be a great addition to the comprehensive … Top institutional shareholders include Primecap Management Co. CA (1.91%), FMR LLC (0.97%), Price T Rowe Associates Inc. MD (0.71%), Fisher Asset Management LLC (0.68%), BlackRock Inc. (0.46%) and Jennison Associates LLC (0.38%). The dividend payout ratio of AstraZeneca is 106.29%. Vote “Outperform” if you believe AZN will outperform the S&P 500 over the long term. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. British American Tobacco acquires nicotine pouch product assets of Dryft. Receive a free world-class investing education from MarketBeat. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Since then, AZN shares have increased by 8.6% and is now trading at $48.42. Discover announcements from companies in your industry. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Viela has sped through the typical biotech milestones, going from newly formed company to commercial drugmaker to acquisition target in just three years. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Crucial data on AstraZeneca's vaccine are coming. Dealmaking, however, appears to be continuing apace. ; Horizon will pay $53 per share for Viela, which in June won U.S. approval for Uplizna, a treatment for the rare autoimmune disease neuromyelitis optica spectrum disorder, or NMOSD. on View institutional ownership trends for AstraZeneca. The P/E ratio of AstraZeneca is 50.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 32.68. Viela's progress has evidently caught the attention of Horizon, a company focused on treatments for rare and rheumatic diseases. AstraZeneca Indonesia, Pearl Therapeutics, Pearl Therapeutics Inc, Pharmaceutical Manufacturing Company Pty Limited, Pharmaceutical Manufacturing Division Pty Limited, SPA AstraZeneca Al Djazair, Simesa SpA, Sofotec GmbH, Spirogen Sarl, Stauffer Management Company LLC, Stuart Pharma Aktiebolag, Stuart-Produtos Farmacêuticos Lda, Symbicom Aktiebolag, Takeda Respiratory Business, Tika Lakemedel Aktiebolag, Trustee Limited, Unipessoal Lda, WuXi MedImmune Biopharmaceutical Co, ZS Pharma, ZS Pharma Inc, Zenco (No.